Single doses of norfloxacin (200, 400 , 800, 1,200, and 1,600 mg) or placebo were administered orally at weekly intervals to 14 healthy male volunteers in a doubleblind study. Norfloxacin was measured in serum and urine by high-pressure liquid chromatography with UV detection. The concentrations of this drug in serum peaked 1 to 2 h after each dose; the mean peak values for increasing doses were 0.75, 1.58, 2.41, 3.15, and 3.87 Fg/ml. Mean area under the serum concentrationtime curves for the first 12 h after each dose were 3.56, 6.26, 11.4, 16.1, and 19.7 ,ug * h/ml, respectively. The elimination half-life of norfloxacin was about 7 h and was similar for all doses. The concentrations of the drug in urine also peaked 1 to 2 h after dosage; mean peak values for increasing doses were 200, 478, 697, 992, and 1,045 ,ug/ml. Renal clearances approximated 285 ml/min. About 30% of each dose was excreted into urine as unmetabolized norfloxacin. Crystals of the drug were occasionally observed during microscopic examination of freshly voided urine collected after the 1,200-and 1,600-mg doses. Crystalluria was not encountered at lower doses.
Norfloxacin (MK-0366) is a new quinoline carboxylic acid which exhibits high antimicrobial activity in vitro against a wide variety ofgramnegative and gram-positive bacteria, including gentamicin-resistant Pseudomonas aeruginosa and ,-lactamase-positive Neisseria gonorrhoeae (2, 3, (5) (6) (7) . In addition, this drug is severalfold more potent than nalidixic acid and pipemidic acid in the treatment of systemic and urinary tract infections in experimental animals (4 days before initiation of the study until completion of all treatment periods.
Study design. In a double-blind manner, volunteers were randomly assigned to receive each of seven oral treatments, including sequentially increasing doses of norfloxacin (200, 400, 800, 1,200, and 1,600 mg) and two randomly interspersed placebos. Volunteers received their medication (four capsules) with 250 ml of water in the morning after an overnight fast. They resumed a normal diet 3 h after drug administration.
Blood from a forearm vein and urine were collected periodically for up to 48 h. During the first 6 h after each treatment, 10 ml of each freshly voided urine specimen was centrifuged at 2,500 x g for 10 min, and the pellet was examined microscopically for the presence of crystals. A period of 6 days separated each treatment.
Analytical methods. The concentration of norfloxacin in urine and serum was measured according to published methods (1). Briefly, specimens were adjusted to pH 7.5 with buffer and extracted with methylene chloride. The drug was concentrated by back-extracting into a small volume of 0.3 N NaOH and then was quantified by high-pressure liquid chromatography with UV detection at 273 nm. This method separates norfioxacin from its metabolites and provides reliable quantitation (i.e., less than 5% variation in replicates) down to 0.1 pLg/ml in serum and 1 Ag/ml in urine. Urine specimens were mixed well before assay to assure uniform sampling.
Area under the serum concentration-time curves (AUCs) were determined by the trapezoidal rule. Serum elimination half-lives were calculated from the slopes of the log concentration versus time plots from 6 to 12 h after dosage, where the slope = -ke and t'/2 = 0.693/kI. Urinary elimination half-lives were calculated from the slopes of the log excretion rate (milligams per hour) versus time plots from 8 to 48 h after dosage; the midpoint of each collection interval was used for computations. Renal clearances were calculated by dividing the amount of urinary norfioxacin (in micrograms) by the serum AUC (micrograms * hour per milliliter).
To assess drug solubility in urine, norfloxacin was added in excess to urine samples that were previously adjusted to pH values between 4 and 10 with small quantities of 6 N HCI or 6 N NaOH. Urine was incubated at 3rC for 4 h with occasional interim adjustments in pH to correct for buffering effects ofthe drug. f Renal clearance = drug excreted/serum AUC (0-to 12-h data).
clearances were large (about 285 ml/min), and urinary drug concentrations were consequently 100-to 300-fold greater than concurrent concentrations in serum (Table 2 ). Approximately 30%6 of each dose was excreted into urine as unmetabolized norfloxacin in the first 48 h after drug administration (Fig. 2) . The urinary solubility of norfloxacin was found to be dependent on both pH and temperature (Fig. 3) . The drug was least soluble at pH 7.5, exhibiting a maximal solubility of about 450 ,ug/ml at 25°C and 1,200 ,ug/ml at 37°C. At 372C, the drug was freely soluble (concentration >40 mg/ml) at any pH value less than or equal to 5.5. Drug crystals were observed in only 5 of over 300 clinical specimens. All five specimens had been collected after 1,200-or 1,600-mg doses and exhibited pH values between 7.0 and 7.8 and drug concentrations between 1,200 and 2,300 ,g/ml. Drug crystals in urine were spherical with ragged edges and orange and green highlights. This was in marked contrast to crystals precipitated from water, which were colorless needles.
Routine laboratory tests for proteinuria, blood urea nitrogen, and serum creatinine indicated that acute doses of norfloxacin were not nephrotoxic. For example, the values for blood urea nitrogen and serum creatinine were 13.7 + 3.9 and 1.10 0.12 mg per 100 ml, respectively, before the first dose and were 14.8 + 3.6 and 1.06 + 0.09 mg per 100 ml 3 days after the last dose.
DISCUSSION
This study has defined several important features of norfloxacin disposition after oral administration. Maximal concentrations in serum and urine were rapidly achieved, typically within 1 to 2 h. Assuming-that norfloxacin is 14% bound to serum proteins (Merck Sharp & Dohme Research Laboratories, personal communication), the free renal clearance for this antibiotic was about 325 ml/min, a remarkable 2.5 times the normal glomerular ifitration rate. Presumably, norfloxacin is actively secreted as an organic acid. However, this antibiotic is both an acid and a base and could also be secreted by other mechanisms. The amphoteric nature of the drug is reflected in its urine solubility curve (Fig. 3) , which shows a trough in solubility at pH 7.5 and greatly enhanced solubility under both more acidic and more basic conditions.
With rising doses, the serum Cm., serum AUC from 0 to 12 h, and the 0-to 12-h urinary recovery of unmetabolized drug all became progressively lower relative to the amount of drug administered. This suggested that the fraction of the dose absorbed over the first 12-h period was lower at the higher doses. However, by 48 h, the mean percent recovery in urine was not substantially different for the various doses (range, 27.4 to 31.0%o), indicating that absorption may have been delayed at the higher doses. These doserelated changes in norfloxacin bio-availabiity may be of no clinical importance, as they occuffed at excessively high doses. Although the apparent serum half-life of norfloxacin in our study was found to be approximately 7 h, accurate calculation of an elimination half-life in serum is not possible if drug absorption is substantially delayed. However, approximately the same half-life can be derived from urinary excretion rates observed after drug absorption processes are complete.
In our study, drug-related crystals were observed only at the highest (1, 200 
